197 related articles for article (PubMed ID: 16365032)
1. Probing the functional link between androgen receptor coactivator and ligand-binding sites in prostate cancer and androgen insensitivity.
He B; Gampe RT; Hnat AT; Faggart JL; Minges JT; French FS; Wilson EM
J Biol Chem; 2006 Mar; 281(10):6648-63. PubMed ID: 16365032
[TBL] [Abstract][Full Text] [Related]
2. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.
Askew EB; Gampe RT; Stanley TB; Faggart JL; Wilson EM
J Biol Chem; 2007 Aug; 282(35):25801-16. PubMed ID: 17591767
[TBL] [Abstract][Full Text] [Related]
3. Structural features discriminate androgen receptor N/C terminal and coactivator interactions.
Askew EB; Minges JT; Hnat AT; Wilson EM
Mol Cell Endocrinol; 2012 Jan; 348(2):403-10. PubMed ID: 21664945
[TBL] [Abstract][Full Text] [Related]
4. Allosteric conversation in the androgen receptor ligand-binding domain surfaces.
Grosdidier S; Carbó LR; Buzón V; Brooke G; Nguyen P; Baxter JD; Bevan C; Webb P; Estébanez-Perpiñá E; Fernández-Recio J
Mol Endocrinol; 2012 Jul; 26(7):1078-90. PubMed ID: 22653923
[TBL] [Abstract][Full Text] [Related]
5. Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction.
Bai S; He B; Wilson EM
Mol Cell Biol; 2005 Feb; 25(4):1238-57. PubMed ID: 15684378
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate.
Powell SM; Christiaens V; Voulgaraki D; Waxman J; Claessens F; Bevan CL
Endocr Relat Cancer; 2004 Mar; 11(1):117-30. PubMed ID: 15027889
[TBL] [Abstract][Full Text] [Related]
7. Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs.
He B; Wilson EM
Mol Cell Biol; 2003 Mar; 23(6):2135-50. PubMed ID: 12612084
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor mutations identified in prostate cancer and androgen insensitivity syndrome display aberrant ART-27 coactivator function.
Li W; Cavasotto CN; Cardozo T; Ha S; Dang T; Taneja SS; Logan SK; Garabedian MJ
Mol Endocrinol; 2005 Sep; 19(9):2273-82. PubMed ID: 15919721
[TBL] [Abstract][Full Text] [Related]
9. Analysis of interdomain interactions of the androgen receptor.
Wilson EM
Methods Mol Biol; 2011; 776():113-29. PubMed ID: 21796524
[TBL] [Abstract][Full Text] [Related]
10. Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region.
Wang Q; Lu J; Yong EL
J Biol Chem; 2001 Mar; 276(10):7493-9. PubMed ID: 11102454
[TBL] [Abstract][Full Text] [Related]
11. Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor.
Dubbink HJ; Hersmus R; Verma CS; van der Korput HA; Berrevoets CA; van Tol J; Ziel-van der Made AC; Brinkmann AO; Pike AC; Trapman J
Mol Endocrinol; 2004 Sep; 18(9):2132-50. PubMed ID: 15178743
[TBL] [Abstract][Full Text] [Related]
12. Communication between the Ligand-Binding Pocket and the Activation Function-2 Domain of Androgen Receptor Revealed by Molecular Dynamics Simulations.
Jin Y; Duan M; Wang X; Kong X; Zhou W; Sun H; Liu H; Li D; Yu H; Li Y; Hou T
J Chem Inf Model; 2019 Feb; 59(2):842-857. PubMed ID: 30658039
[TBL] [Abstract][Full Text] [Related]
13. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor.
He B; Kemppainen JA; Wilson EM
J Biol Chem; 2000 Jul; 275(30):22986-94. PubMed ID: 10816582
[TBL] [Abstract][Full Text] [Related]
14. The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor.
Estébanez-Perpiñá E; Moore JM; Mar E; Delgado-Rodrigues E; Nguyen P; Baxter JD; Buehrer BM; Webb P; Fletterick RJ; Guy RK
J Biol Chem; 2005 Mar; 280(9):8060-8. PubMed ID: 15563469
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance.
He B; Gampe RT; Kole AJ; Hnat AT; Stanley TB; An G; Stewart EL; Kalman RI; Minges JT; Wilson EM
Mol Cell; 2004 Nov; 16(3):425-38. PubMed ID: 15525515
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping.
Dubbink HJ; Hersmus R; Pike AC; Molier M; Brinkmann AO; Jenster G; Trapman J
Mol Endocrinol; 2006 Aug; 20(8):1742-55. PubMed ID: 16627595
[TBL] [Abstract][Full Text] [Related]
17. The in vivo role of androgen receptor SUMOylation as revealed by androgen insensitivity syndrome and prostate cancer mutations targeting the proline/glycine residues of synergy control motifs.
Mukherjee S; Cruz-Rodríguez O; Bolton E; Iñiguez-Lluhí JA
J Biol Chem; 2012 Sep; 287(37):31195-206. PubMed ID: 22829593
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of ligand-dependent changes in AR structure using peptide probes.
Chang CY; McDonnell DP
Mol Endocrinol; 2002 Apr; 16(4):647-60. PubMed ID: 11923463
[TBL] [Abstract][Full Text] [Related]
19. Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions.
Duff J; McEwan IJ
Mol Endocrinol; 2005 Dec; 19(12):2943-54. PubMed ID: 16081517
[TBL] [Abstract][Full Text] [Related]
20. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor.
Haelens A; Tanner T; Denayer S; Callewaert L; Claessens F
Cancer Res; 2007 May; 67(9):4514-23. PubMed ID: 17483368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
